Physician profile
Jennifer E Lambert
NPI 1477851830
$5,470.44
in general payments reported to CMS, 2019-2025
30 companies · $957 in 2025
The $957 reported for 2025 was more than what 96% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,270 · 2022: $613 · 2023: $990 · 2024: $641 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.59 |
| Education | $161.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $2,852.57 | 2021-2024 | Axonics |
| Abbvie INC. | $701.60 | 2022-2025 | |
| Astellas Pharma US INC | $247.08 | 2021-2023 | Veozah |
| Boston Scientific Corporation | $233.99 | 2022-2025 | Axonics |
| Janssen Biotech, INC. | $173.62 | 2024-2025 | Erleada, Akeega, Balversa |
| Urogen Pharma, INC. | $144.56 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $128.04 | 2023-2025 | Gemtesa, Orgovyx |
| Mayne Pharma Commercial LLC | $84.10 | 2023-2025 | |
| Therapeuticsmd, INC. | $77.17 | 2021-2022 | |
| Pfizer INC. | $69.81 | 2021-2022 | |
| Urovant Sciences INC | $69.39 | 2022 | |
| Antares Pharma, INC. | $68.13 | 2024-2025 | Xyosted |
| Scynexis, INC. | $62.27 | 2022 | |
| Ascend Therapeutics US, LLC | $59.04 | 2022-2023 | |
| Medtronic, INC. | $58.13 | 2023-2025 | Nuro |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $57.78 | 2023-2025 | Prolaris |
| Procept Biorobotics Corporation | $50.92 | 2024 | Aquabeam System |
| Millicent US INC | $41.72 | 2024-2025 | Intrarosa, Femring |
| Novartis Pharmaceuticals Corporation | $37.60 | 2024-2025 | |
| Immunitybio, INC. | $34.39 | 2025 | |
| Coloplast Corp | $33.72 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $32.86 | 2025 | Magic3 Go Intermittent Urinary Catheter |
| Merck Sharp & Dohme LLC | $31.50 | 2021-2025 | Keytruda |
| Mycovia Pharmaceuticals, INC. | $25.57 | 2022 | |
| 180 Medical, INC. | $21.70 | 2025 | Gentlecath Glide |
| Endo Pharmaceuticals INC. | $19.74 | 2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $16.75 | 2025 | |
| Ambu INC. | $13.51 | 2025 | |
| Halozyme INC | $12.96 | 2023 | |
| Allegis Pharmaceuticals, LLC | $10.22 | 2023 | Urimar-T Caps |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lambert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.